SLC5A2 and atherosclerosis: While GLP‐1 receptor agonists and SGLT‐2 inhibitors both demonstrated similar increases in utilization for patients with high ASCVD risk, SGLT‐2 inhibitors were more commonly used across incident patients of other risk categories.